Erste Group Bank Comments on Gilead Sciences FY2027 Earnings

Key Points

• Erste Group Bank raised its FY2027 EPS estimate for Gilead Sciences slightly to $9.90 from $9.88.
• Analyst sentiment remains broadly positive, with 23 Buy ratings and six Holds contributing to a “Moderate Buy” consensus and an average price target of $159.33.
• Gilead’s latest quarter exceeded expectations, generating $7.80 billion in revenue and negative EPS of $6.75, while the company maintains a quarterly dividend of $0.82, or $3.28 annually.

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Stock analysts at Erste Group Bank boosted their FY2027 earnings per share (EPS) estimates for Gilead Sciences in a research report issued on Thursday, October 8th. Erste Group Bank analyst H. Engel now anticipates that the biopharmaceutical company will post earnings per share of $9.90 for the year, up from their prior estimate of $9.88. The consensus estimate for Gilead Sciences' current full-year earnings is ($0.47) per share.

Other research analysts have also issued reports about the stock. Barclays lowered their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 29th. Truist Financial lifted their price target on shares of Gilead Sciences from $150.00 to $158.00 and gave the company a "buy" rating in a research report on Wednesday, October 7th. Bank of America reiterated a "buy" rating and set a $164.00 price target on shares of Gilead Sciences in a research report on Monday. Zacks Research lowered Gilead Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 29th. Finally, Royal Bank Of Canada upped their price target on Gilead Sciences from $123.00 to $126.00 and gave the stock a "sector perform" rating in a report on Thursday, October 8th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $159.33.

Gilead Sciences Stock Down 0.5%

Shares of NASDAQ GILD opened at $150.43 on Tuesday. The stock has a market capitalization of $186.53 billion, a price-to-earnings ratio of -56.34 and a beta of 0.31. Gilead Sciences has a 52 week low of $114.02 and a 52 week high of $157.29. The firm has a 50-day moving average price of $145.51 and a 200 day moving average price of $136.80. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion for the quarter, compared to analysts' expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business's revenue for the quarter was up 10.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.01 EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of GILD. Strategic Investment Solutions Inc. IL bought a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $25,000. Persistent Asset Partners Ltd acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $25,000. Kimelman & Baird LLC acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $25,000. Wealth Preservation Advisors LLC raised its position in shares of Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 81 shares during the period. Finally, Wiser Advisor Group LLC bought a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $30,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the firm's stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the transaction, the director directly owned 10,066 shares in the company, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of Gilead Sciences stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the transaction, the director owned 12,894 shares of the company's stock, valued at approximately $1,916,306.28. The trade was a 58.26% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 105,000 shares of company stock worth $14,940,540 in the last three months. Company insiders own 0.30% of the company's stock.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend was Tuesday, September 15th. Gilead Sciences's dividend payout ratio is presently -122.85%.

About Gilead Sciences

Gilead Sciences, Inc NASDAQ: GILD is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead's portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.